Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1710-1721

  Paramita, Dewi K ^a   Fachiroh, Jajah ^a   Artama, Wayan T ^a   Van Benthem, Eric ^b   Haryana, Sofia M ^a   Middeldorp, Jaap M ^b  

^a GADJAH MADA UNIVERSITY   (Indonesia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Early antigen; Epstein Barr virus; IgA ELISA; Nasopharyngeal carcinoma; Serology

Indexed keywords

EARLY ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT ANTIGEN; TUMOR MARKER;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFECTIOUS MONONUCLEOSIS; NASOPHARYNX CARCINOMA; NONHUMAN; SENSITIVITY AND SPECIFICITY; SERUM;

ANIMALS; ANTIGENS, VIRAL; BACULOVIRIDAE; CELL LINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NASOPHARYNGEAL NEOPLASMS; RECOMBINANT PROTEINS; SPODOPTERA;

HUMAN HERPESVIRUS 4; MIRIDAE;

EID: 34748892619     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20987     Document Type: Article

References (58)

1. Chan KR, Luo RX, Chen HL, MH NG, Seto WH, Peiris JSM. 1998. Development and evaluation of an Epstein-Barr Virus (EBV) Immunoglobulin M Enzyme-linked immunosorbent assay based on the 18-kilodalton matrix protein for diagnosis of primary EBV infection. J Clin Microbiol 36:3359-3361.
2. Cheng HM, Foong YT, Sam CK, Prasad U, Dillner J. 1991. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol 10:2180-2186.
3. Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, Zheng BJ, Ji MF, Liang JS, Sham JS, Wang DK, Zong YS, Ng MH. 2002. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 97:489-492.
4. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345:1877-1882.
5. Connolly Y, Littler E, Sun N, Chen X, Hyang PC, Stacey SN, Arrand JR. 2001. Antibodies to Epstein-Barr virus thymidine kinase: A characteristic marker for the serology detection of nasopharyngeal carcinoma. Int J Cancer 19:692-697.
6. Crowther JR. 2001. Validation of diagnostic test for infectious disease. In: The ELISA guidebook (methods in Molecular biology vol. 149). Humana Press, Inc.: Totowa NJ. pp 301-346.
7. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, Benslimane A, Khyatti M. 2000. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: Complementary test of ZEBRA protein and early antigen p54 and p138. J Clin Microbiol 39:3164-3170.
8. Deng H, Zeng Y, Lei Y, Zhao Z, Wang P, Li B, Pi Z, Tan B, Zheng Y, Pan W. 1995. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J (Engl) 108:300-303.
9. de Vathaire F, Sancho-Garnier H, de Thé H, Pieddeloup C, Schwab G, Ho JH, Ellousz R, Michaeu C, Cammoun M, Cachin Y, de Thé G. 1988. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 42:176-181.
10. Dolken G, Hecht T, Weitzmann U, Wagner M, Lohr GW, Hirsch FW. 1986. Purification of a polypeptide complex (p52) belonging to the D-subspecificites of Epstein-Barr virus-induced early antigens. Virology 148:58-73.
11. Dolken G, Weitzmann U, Boldt C, Bitzer M, Brugger W, Lohr GW. 1984. Detection of IgA antibodies to Epstein-Barr virus-associated antigens by ELISA. J Immunol Meth 68:331-339.
12. Dopatka HD, Schuy W. 1996. Compact Epstein-Barr virus diagnosis based on a defined antigen mix and specific IgA. Res Virol 147: 53-66.
13. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM. 2004. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopbaryngeal carcinoma: A comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190:53-62.
14. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng Y, Schouten T, Mubarika S, Middeldorp JM. 2006. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: Options for field screening. J Clin Microbiol 44:1459-1467.
15. Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley ML. 2004. Laboratory markers of tumor burden in nasopharyngeal carcinoma: A comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 112:1036-1041.
16. Gartner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N. 2003. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol 10:78-82.
17. Gray JJ. 1995. Avidity of EBV VGA-specific IgG antibodies: Distinction between recent primary infection, past infection and reactivation. J Virol Meth 52:95-104.
18. Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P, DeSchryver A, de The G, Diehl V, Klein G. 1970. Antibodies to Epstein Barr Virus in nasopharyngeal carcinoma, other head and neck neoplasm and control groups. J Natl Cancer Inst 44:225-231.
19. Henle G, Henle W. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1-7.
20. Henle W, Ho HHC, Henle G, Chau JCW, Kwan HC. 1977. Nasopharyngeal carcinoma: Significance of changes in Epstein-Barr virus-related antibody pattern following therapy. Int J Cancer 20:663-672.
21. Joab I, Nicolas JC, Schwaab G, de-The G, Clausse B, Perricaudet M, Zeng Y. 1991. Detection of anti-Epstein-Barr virus transactivator, Zebra, antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 48:647-649.
22. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM. 2005. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 75:593-602.
23. Lanier AP, Henle W, Bender TR, Henle G, Talbot M. 1980. Epstein-Barr virus specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Int J Cancer 26: 133-137.
24. Liu MY, Huang YT, Sheen TS, Chen JY, Tsai CH. 2004. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma. J Med Virol 73:574-582.
25. Lu CC, Chen MR. 2006. Lytic replication of Epstein-Barr virus. Future Virol 1:435-446.
26. Luka J, Siegert W, Klein G. 1977. Solubilization of Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA binding protein. J Virol 22:1-8.
27. Meij P, Vervoort MB, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJ, Middeldorp JM. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 179:1108-1115.
28. Meij P, Vervoort MB, de Gooijer K, Bloemena E, Meijer CJ, Middeldorp JM. 2000. Bioreactor-scale production and one-step purification of Epstein-Barr nuclear antigen 1 expressed in baculovirus-infected insect cells. Protein Expr Purif 20:324-333.
29. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM. 2002. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol 68:370-377.
30. Middeldorp JM, Herbrink P. 1988. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Meth 21:133-146.
31. Middeldorp JM. 1998. Epstein-Barr virus peptides and antibodies against these peptides AKZO NOBEL patent U S58443405.
32. Middeldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. 2003. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45:1-36.
33. Naegele RF, Champion J, Murphy S, Henle G, Henle W. 1982. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis. Int J Cancer 29:209-212.
34. Raab-Traub N. 2002. Epstein Barr-Virus in the pathogenesis of nasopharyngeal carcinoma. Semin Cancer Biol 12:431-441.
35. Rowe M, Finke J, Szigeti R, Klein G. 1988. Characterization of the serological response in man to the latent membrane protein and six nuclear antigen encoded by Epstein-Barr virus. J Gen Virol 69: 1217-1228.
36. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D, Middeldorp J, Wiertz EJ, Ressing ME. 2007. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 104:3366-3371.
37. Sigel G, Schillinger M, Henninger K, Bauer G. 1994. IgAdirected against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma. J Med Virol 43:222-227.
38. Soeripto. 1998. Epidemiology of nasopharyngeal carcinoma. Berita Kedokteran Masyarakat XIII:207-211.
39. Stevens SJC, Verkuijlen SAWM, Zwaan MC, Middeldorp JM. 2006. Epstein-Barr virus (EBV) serology, but not EBV DNA load, for predicting distant metastases in a juvenile Caucasian nasopharyngeal carcinoma (NPC) patient without clinical response upon EBV lytic induction therapy. Head Neck 28:1040-1045.
40. Stolzenberg MC, Debouze S, Ng M, Sham J, Choy D, Bouguermouh A, Chan KH, Ooka T. 1996. Purified recombinant EBV desoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma. Int J Cancer 66:337-341.
41. Teo PM, Chan AT. 2002. Treatment strategy and clinical experience. Semin Cancer Biol 12:497-504.
42. Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA. 2004. Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: A three-year institutional review. Head Neck 26:598-602.
43. Tsurumi T, Kobayashi A, Tamai K, Yamada H, Daikoku T, Yamashita Y, Nishiyama Y. 1996. Epstein-Barr virus single stranded DNA-binding protein: Purification, characterization and action on DNA synthesis by the viral polymerase. Virology 222:352-364.
44. Uen WC, Luka J, Pearson GR. 1988. Development of an enzyme-linked immunosorbent assay (ELISA) for detecting IgA antibodies to the Epstein-Barr virus. Int J Cancer 41:479-482.
45. van Grunsven WJM, Nabbe A, Middeldorp JM. 1993a. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 40:161-169.
46. van Grunsven W, van Heerde E, de Haard H, Spaan WJM, Middeldorp JM. 1993b. Gene mapping and prokaryotic expression of two immunodominant Epstein Barr viral capsid proteins. J Virol 67:3908-3916.
47. van Grunsven WJM, Spaan WJM, Middeldorp JM. 1994. Localisation and diagnostic application of immunodominan domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 170:13-19.
48. Wei WI, Sham JS. 2005. Nasopharyngeal carcinoma. Lancet 365:2041-2054.
49. Wielaard F, Scherders J, Dagelinckx C, Middeldorp JM, Sabbe LJ, Van Belzen C. 1988. Development of an antibody-capture IgM-enzyme-linked immunosorbent assay for diagnosis of acute Epstein-Barr virus infections. J Virol Meth 21:105-115.
50. Wolf H, zur Hausen H, Becker V. 1973. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nature New Biol 244:245-247.
51. Wong MM, Lye MS, Cheng HM, Sam CK. 2005. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. Asian Pac J Allergy Immunol 23:65-67.
52. WHO-IARC. 1997 Epstein-Barr virus. IARC monographs on the evaluation of carcinogenic risks in humans. Lyon: Publ. IARC Press. vol. 70. 47-373.
53. Yi Z, Yuxi L, Chrunen L, Sanwen C, Jihneng W, Jisong Z, Huijong Z. 1980. Application of immunoenzymatic method and immunoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 13:162-168.
54. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757-768.
55. Zeng Y. 1985. Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res 44:121-138.
56. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Su GR. 1982. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou city, Cbina. Int J Cancer 29:139-141.
57. Zeng Y, Middeldorp JM, Madjar JJ, Ooka T. 1997. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 239:285-295.
58. Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, Middeldorp JM, Sham JS, Griffin BE, Ng MH. 1998. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 55: 227-233.